España
MSTX
Pero mejor verlo en esta web que nos aporto Anaramos
http://investing.money.msn.com/investments/analyst-ratings/?symbol=MSTX
Leanse-> Analista Rating - Insider Trades y Ownership
Zacks average brokerage recommendation is Strong Buy
-->
Con esos datos vaya como para hincharse de MSTX si todo esas reco. se cumplen, tenemos para 7 años de exclusividad de mercado
Saludos y buen provecho
amiga zoka que opinas de Keryx Biopharmaceuticals(NASDAQ:KERX) ahora mstx se mantiene con poco volumen luego es positivo para el que quiere entrar saludos
amiga zoka que bueno recuperamos ahora a ganar $$$ pero va hacer lento creo Mast Therapeutics, Inc. (MSTX) -AMEX
0.50 Up 0.03(6.11%) 1:35PM EDT - Nasdaq Real Time Price
MSTX
--->> Haciendo un Golden Cross MM.50/100
http://stockcharts.com/h-sc/ui
El prox 04/11/ Presenta Q-3 q se espera sea + y despues debe presentar F-III y despues FDA
La tiene clavada en 0.48/0.50 desde hace huuuu atraves Trading Software
SHORT SHELLING INSTEREST EN PICADA----> vease el grafico
http://www.nasdaq.com/symbol/mstx/short-interest
Amiga zoka mira esto es interesante http://www.macroaxis.com/invest/market/MSTX--Mast-Therapeutics-Inc
Muy interesante, datos y análisis completo e integral, con eso y un poco de A.Tecnico tenemos buena orientación. Gracias
– Japan
On October 30, an online article in The Japan News, discusses how Japan’s Health, Labor and Welfare Ministry submits a proposal to review the country’s public assistance system for patients with rare or intractable diseases. Currently, the Japanese government subsidizes medical expenses of patients who suffer from 56 rare diseases. If the disease is severe, the government covers all of the medical expenses. Under the new proposed plan:
• Patients with rare diseases will be responsible for 20% of their medical expenses
• There is a cap on the amount patients have to pay, depending on household income
• Number of rare diseases will increase from 56 to 300.
After reaching a conclusion next month on how to handle rare diseases financially, the Ministry will introduce a new law that becomes effective in January 2015.
II – Australia
On October 25, Australia’s PBAC (Pharmaceutical Benefits Advisory Committee), following a decision in July 2013 to defer a recommendation on the reimbursement of Vertex Pharmaceutical’s orphan drug Kalydeco (Ivacaftor) for Cystic Fibrosis (CF), has decided again to defer a decision – until March 2014. Vertex Pharmaceuticals needs to submit their submission by November 6. About 200 CF patients who have the G551D mutation qualify for Kalydeco.
The alphabetical list of designated orphan drugs in Australia, from the Australian
http://orphandruganaut.wordpress.com/2013/10/31/rare-diseases-and-orphan-drugs-global-news-10-31-13/
MSTX
Some Very Good DD about this Situation:
Some DD information for the thoughtful investor...
One of the most exciting biotechnology companies in the market today is Mast Therapeutics (MSTX), a little known company developing an Orphan designated investigational agent (MST-188) that has potential to reduce ischemic tissue injury and end organ damage by restoring microvascular function. MSTX's current clinical focus is on two Orphan diseases: Sickle Cell Anemia ("SCD") and Acute Limb Ischemia ("ALI"). MSTX has already received Orphan Designation for SCD in the U.S and EU, and for ALI in the EU. The stock currently trades at 30 percent below its cash position, has no debt, and existing financial resources are more than adequate to fund the ongoing Phase 3 study in SCD, Phase 2 study in ALI, as well as additional studies for other indications. With a potential pharmaceutical treatment for multiple medical conditions affecting millions worldwide, MSTX is a significantly undervalued biotech with exponential upside.